Skip to main content

Procedure of IV selection!

 IV DRUG THERAPY- SELECTION OF EQUIPMENTS AND INSERTION OF CATHETER

Equipment:

  1. Canula selection:

Select cannula based on purpose and duration of use and age of patient.

Consider risk of infection and extravasation.

Cannula made from polyurethanes are associated with decreased risk of phlebitis.

Steel needles have higher risk of extravasation and should be avoided where tissue necrosis is likely if extravasation occurs.

      2. Skin Prep:

Antiseptic solution, use an aqueous based alternative if there is a known allergy to alcohol.

      3. Other Equipment:

Intravenous solution as ordered, torniquet, giving set, IV stand/pole, infusion pump, transparent occlusive dressing, tape or similar to secure cannula, gloves, paper bag.

      4. Additional Equipment which may be required:

Syring (5mL), sterile sodium chloride 0.9%, local anesthetics (in children), 3-way tap or triflow, short extension tube.



Selection Of the Catheter Site:

  1. Generally speaking, the vein section with the straightest appearance should be selected.
  2. A vein that has a firm, round appearance or feel when palpated should be chosen and areas where the vein crosses over joints should be avoided.
  3. In adults, use long straight veins in an upper extremity away from the joints for catheter insertion-in preference to sites on the lower extremities.
  4. If possible, avoid veins in the dominant hand and use distal veins first.
  5. Do not insert cannula on the site of mastectomy or AV shunts.
  6. In pediatric, it is recommended that the cannula be inserted into scalp, hand, or foot site in preference to a leg, arm, or ante cubital fossa site.


Procedure:

1. Explain procedure to patient/parent.

2. Wash hands with antiseptic soap, put on gloves,

3. Apply the torniquet above insertion,

4. Disinfect the selected site with skin prep and allow to dry, do not touch the skin with the fingers after preparation solution has been applied.

5. Inspect the cannula before insertion to ensure that the needle is fully inserted into the plastic cannula and that the cannula tip is not damaged,

6. Ensure the level of the cannula is facing upwards.



Labels:

Comments

Post a Comment

Popular posts from this blog

Diabetes Mellitus: Types!

TYPES OF DIABETES MELLITUS 1. TYPE1 DM Type 1 DM is usually diagnosed before age 30 years, but it can develop at any age. T1DM is an autoimmune disease in which insulin producing B-cells are destroyed. The presence of Human Leucocyte Antigens (HLAs ) is associated with the development of T1DM. In addition, these individuals often develop Islet cell antibodies , Insulin Autoantibodies or Glutamic Acid decarboxylase autoantibodies . At the time of development of diagnosis of T1DM, it is usually believed that most of the patients have 80-90%loss of beta cells. The remaining beta cells function at the diagnosis creates a " HONEYMOON PERIOD" during which the blood glucose levels are easier to control, and smaller amounts of insulin are required. after this, the remaining beta cells function is completely lost, and the patients become completely deficient of insulin and hence require exogenous insulin.  2. TYPE1.5 DM:  Also referred as Latent autoimmune diabetes in Adults (LAD) ...
Post a Comment
Read more

Diabetes Mellitus: Pharmacotherapy- Gliptins and a-Glycoside Inhibitors!

  PHARMACOTHERAPY:  Medications classifications include:  Sulfonyl Urea's Nonsylfonylurea Secretagogues (a-Glinides) Biguanides Thiazolidinediones a-Glucosidase Inhibitors Dipeptidyl Peptidase-4 Inhibitors (Gliptins) Sodium-glucose co-transporter (SGLT) Inhibitors  Central-Acting Dopamine Agonists Bile Acid Sequestrants Insulin therapy 5. a-GLUCOSIDASE INHIBITORS Acarbose and Miglitol are a-glucosidase inhibitors currently approved in the United States. Mechanism of Action: An enzyme that is along the brush border of the intestine cells called a-glucosidase; breaks down the complex carbohydrates into simple sugars, resulting in absorption. The a-glucosidase inhibitors work by delaying the absorption of carbohydrates from the intestinal tract, which reduces the rise in postprandial glucose levels. Therapy: As a monotherapy , a-glucosidase inhibitors primarily reduce post-prandial glucose excursions.  Clinical Use: FPG concentrations have been decreased by 40-5...
Post a Comment
Read more

Drug-Induced Nephrotoxicity!

 DRUG-INDUCED NEPHROTOXICITY Drug-Induced Nephrotoxicity is increasingly recognized as a significant contributor to kidney disease including Acute Kidney Injury (KI) and chronic kidney disease (CKD). Nephrotoxicity has a wide spectrum, reflecting damage to different nephron segments based upon individual drug-mechanisms. 1. ACE-INHIBITORS: ACE-Inhibitors are frequently associated with Proteinuria and Renal Insufficiency. The prevalence of Proteinuria in Captopril treated patient is estimated to be 1%. The risk of Renal Insufficiency is greater with long-acting ACE Inhibitors such as Lisinopril or Enalapril than with Captopril. Immune complex glomerulopathy is a major contribute to ACE Inhibitor nephrotoxicity. Predisposing factors include: Hyponatremia Diuretic therapy Pre-existing renal impairment Congestive Heart Failure (CHF) Diabetes Mellitus Recovery of renal function usually follows ACE-Inhibitor discontinuation. 2. CEPHLOSPORIN: The cephalosporin antibiotics are capable of...
Post a Comment
Read more